Abstract: Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotoxicity remain unclear. In this review, we discuss the pharmacological properties of ibrutinib, the incidence and mechanisms of ibrutinib-induced cardiotoxicity, and practical management to prevent and treat this condition. We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors.

Keywords: ibrutinib, cardiotoxicity, BTK inhibitors, atrial fibrillation, cardio-oncology


中文翻译：

---

依鲁替尼相关的心脏毒性：从药物到临床

摘要：依鲁替尼是一流的布鲁顿酪氨酸激酶 (BTK) 抑制剂，它彻底改变了 B 细胞恶性肿瘤的治疗。不幸的是，心脏毒性发生率的增加限制了它的使用。尽管进行了十多年的研究，但依鲁替尼心脏毒性的生物学机制仍不清楚。在这篇综述中，我们讨论了依鲁替尼的药理特性、依鲁替尼诱导的心脏毒性的发生率和机制，以及预防和治疗这种情况的实际管理。我们还概述和讨论了与其他更具选择性的 BTK 抑制剂相关的心血管不良反应，这可能会指导选择合适的 BTK 抑制剂。

关键词：依鲁替尼，心脏毒性，BTK抑制剂，心房颤动，心脏肿瘤学